info@toclinics.com
info@toclinics.com

Risorse

Pubblicazioni

  • Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
    (2021) Leukemia
    ___
  • Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
    (2021) Leukemia
    ___
  • Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice
    (2021) Leukemia
    ___
  • IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
    (2021) Frontiers in Oncology
    ___
  • How I diagnose and treat NPM1-mutated AML
    (2021) Blood
    ___
  • Actinomycin d targets npm1c-primed mitochondria to restore pml-driven senescence in aml therapy
    (2021) Cancer Discovery
    ___
  • NPM1-mutated acute myeloid leukemia: From bench to bedside
    (2020) Blood
    ___
  • Enasidenib and ivosidenib in AML
    (2020) Minerva Medica
    ___
  • GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations
    (2019) Leukemia
    ___
  • BRAF V600E mutation in hairy cell leukemia: From bench to bedside
    (2016) Blood
    ___
  • Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia
    (2015) New England Journal of Medicine
    ___
  • Dactinomycin in NPM1-Mutated acute myeloid leukemia
    (2015) New England Journal of Medicine
    ___
  • Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells
    (2015) Blood
    ___
  • Mouse models of NPM1-mutated acute myeloid leukemia: Biological and clinical implications
    (2015) Leukemia
    ___
  • Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics
    (2015) British Journal of Haematology
    ___
  • The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model
    (2013) Blood
    ___
  • Mutational landscape of AML with normal cytogenetics: Biological and clinical implications
    (2013) Blood Reviews
    ___
  • CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice
    (2010) Blood

Contatti e info

toClinics s.r.l.s.

Via G. Duranti, 67
06100 Perugia, Italy
C.F./P.Iva 03817540549

+39-123-45-67-890

info@toclinics.com
info@pec.toclinics.com

Social Info

“

Siamo un servizio di sperimentazione farmacologica preclinica di precisione, ad elevata specializzazione, gestione condivisa e portfolio di modelli unici.

toClinicsLa nostra mission è la lotta ai tumori